ReviewAntioxidants (Basel, Switzerland)2021
Improving Cognition with Nutraceuticals Targeting TGF-β1 Signaling.
Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Histidine-Containing Dipeptides in Obesity and Cardiometabolic Health: A Systematic Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Article
- Fabrication and appraisal of targeted axitinib loaded bilosomes for the enhanced breast and ovarian anticancer activity.PloS one · 2025Article
- Serotonin enhances neurogenesis biomarkers, hippocampal volumes, and cognitive functions in Alzheimer's disease.Molecular brain · 2024Article
- TGF-β Signaling in Microglia: A Key Regulator of Development, Homeostasis and Reactivity.Biomedicines · 2024Review
- Inflammaging and Brain Aging.International journal of molecular sciences · 2024Review
- Natural Phenolic Compounds with Neuroprotective Effects.Neurochemical research · 2024Review
- Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning.CNS neuroscience & therapeutics · 2023Article
- Augmentation of transforming growth factor-β signaling for the treatment of neurological disorders.Neural regeneration research · 2023Article
- The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Dietary Fats and Cognitive Status in Italian Middle-Old Adults.Nutrients · 2023Article
- Dietary Fats and Depressive Symptoms in Italian Adults.Nutrients · 2023Article
- Neuroprotective Potentials of Flavonoids: Experimental Studies and Mechanisms of Action.Antioxidants (Basel, Switzerland) · 2023Review
- Selected Biomarkers of Depression: What Are the Effects of Cytokines and Inflammation?International journal of molecular sciences · 2022Review
- Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route:Drug delivery · 2022Article
- The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.Molecules (Basel, Switzerland) · 2022Review
- Fluoxetine Ecofriendly Nanoemulsion Enhances Wound Healing in Diabetic Rats: In Vivo Efficacy Assessment.Pharmaceutics · 2022Article
- TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.Biomedicines · 2022Review
- Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper.Molecules (Basel, Switzerland) · 2022Review
- Phenolic Acids and Prevention of Cognitive Decline: Polyphenols with a Neuroprotective Role in Cognitive Disorders and Alzheimer's Disease.Nutrients · 2022Review
- Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rescue of cognitive function represents an unmet need in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD). Nutraceuticals deliver a concentrated form of a presumed bioactive(s) agent(s) that can improve cognitive function alone or in combination with current approved drugs for the treatment of cognitive disorders. Nutraceuticals include different natural compounds such as flavonoids and their subclasses (flavan-3-ols, catechins, anthocyanins, and flavonols), omega-3, and carnosine that can improve synaptic plasticity and rescue cognitive deficits through multiple molecular mechanisms. A deficit of transforming growth factor-β1 (TGF-β1) pathway is an early event in the pathophysiology of cognitive impairment in different neuropsychiatric disorders, from depression to AD. In the present review, we provide evidence that different nutraceuticals, such as
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.